2-(2,4-dimethylphenoxy)-6-(3-fluoro-5-propan-2-yloxyphenyl)-N-(1H-pyrazol-5-ylsulfonyl)pyridine-3-carboxamide
C26H25FN4O5S — CID 121250923
Data last refreshed: (MolForge compound catalog, from PubChem)
About 2-(2,4-dimethylphenoxy)-6-(3-fluoro-5-propan-2-yloxyphenyl)-N-(1H-pyrazol-5-ylsulfonyl)pyridine-3-carboxamide
2-(2,4-dimethylphenoxy)-6-(3-fluoro-5-propan-2-yloxyphenyl)-N-(1H-pyrazol-5-ylsulfonyl)pyridine-3-carboxamide (PubChem CID 121250923) has the molecular formula C26H25FN4O5S and a molecular weight of 524.57 g/mol. Its IUPAC name is 2-(2,4-dimethylphenoxy)-6-(3-fluoro-5-propan-2-yloxyphenyl)-N-(1H-pyrazol-5-ylsulfonyl)pyridine-3-carboxamide.
Molecular Properties
| Compound Name | 2-(2,4-dimethylphenoxy)-6-(3-fluoro-5-propan-2-yloxyphenyl)-N-(1H-pyrazol-5-ylsulfonyl)pyridine-3-carboxamide |
|---|---|
| PubChem CID | 121250923 |
| Molecular Formula | C26H25FN4O5S |
| Molecular Weight | 524.57 g/mol |
| Exact Mass | 524.15 |
| IUPAC Name | 2-(2,4-dimethylphenoxy)-6-(3-fluoro-5-propan-2-yloxyphenyl)-N-(1H-pyrazol-5-ylsulfonyl)pyridine-3-carboxamide |
| SMILES | Cc1ccc(Oc2nc(-c3cc(F)cc(OC(C)C)c3)ccc2C(=O)NS(=O)(=O)c2ccn[nH]2)c(C)c1 |
| InChI | InChI=1S/C26H25FN4O5S/c1-15(2)35-20-13-18(12-19(27)14-20)22-7-6-21(25(32)31-37(33,34)24-9-10-28-30-24)26(29-22)36-23-8-5-16(3)11-17(23)4/h5-15H,1-4H3,(H,28,30)(H,31,32) |
| InChIKey | GFVXANDWZZGMIL-UHFFFAOYSA-N |
| XLogP | 4.93 |
| TPSA | 123.27 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 37 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 524.57 |
| LogP ≤ 5 | 4.93 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 121250923 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.